Clinical Trial

A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 11, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
TQB2101 for Injection is an Antibody-Drug Conjugate (ADC) targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.
Trial Details
NCT Number NCT07113925
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Advanced Hematologic Malignancies
Enrollment 114 participants
Start Date 2025-08-01
Primary Completion 2025-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-11